PROTECTIVE VACCINE BASED ON STAPHYLOCOCCUS AUREUS SA2074 PROTEIN
The present invention relates to methods of inducing an immune response to Staphylococcus comprising administering a composition comprising an SA2074-related polypeptide from Staphylococcus aureus as well as derivatives or fragments thereof. The present invention also encompasses methods of treating and/or reducing the likelihood of a Staphylococcus infection by administering a composition comprising an SA2074-related polypeptide or an antibody that specifically binds to an SA2074 polypeptide, derivative or fragments thereof. Compositions administered in the methods of the invention can include one or more additional antigens. Compositions used to practice the methods of the invention are also encompassed.
1 . A composition comprising an immunologically effective amount of a polypeptide that is at least 95% identical to SEQ ID NO:1 or a fragment of the polypeptide and a pharmaceutically acceptable carrier; wherein the polypeptide is not SEQ ID NO:1.
2 . The composition of claim 1 wherein the polypeptide is at least 98% identical to SEQ ID NO:1.
3 . The composition of claim 2 further comprising one or more additional S. aureus antigens.
4 . The composition of claim 2 wherein the composition further comprises an adjuvant.
5 . A method of inducing a protective immune response in a patient against an S. aureus infection comprising the steps of administering to the patient an immunologically effective amount of the composition of any of claim 4 .
6 . The method of claim 5 wherein the patient is human or a non-human mammal.
7 . The method of claim 6 wherein the patient has weakened immunity, has received a foreign body implant or is on renal dialysis.
8 . The method of claim 7 wherein the patient that weakened immunity has HIV or AIDS.
9 . The method of claim 7 wherein the foreign body implant is a catheter, a vascular device, pacemaker leads, defibrillator systems, or prosthetic heart valve.
10 - 16 . (canceled)
17 . A method of conferring passive immunity to S. aureus infection in a patient comprising administering to the patient one or more antibodies that specifically bind to a polypeptide of SEQ ID NO:1.
18 . The method of claim 17 wherein the one or more antibodies are monoclonal antibodies.
19 . The method of claim 18 wherein the one or more antibodies are selected from the group consisting of human antibodies and humanized antibodies.
20 . The composition of claim 3 , further comprising an adjuvant.